DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Vyvanse (Lisdexamfetamine Dimesylate) - Published Studies

 
 



Vyvanse Related Published Studies

Well-designed clinical trials related to Vyvanse (Lisdexamfetamine)

Dose response effects of lisdexamfetamine dimesylate treatment in adults with ADHD: an exploratory study. [2012]

Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis. [2011.11.04]

Prediction of placebo response in 2 clinical trials of lisdexamfetamine dimesylate for the treatment of ADHD. [2011.10]

Effect of lisdexamfetamine dimesylate on sleep in children with ADHD. [2011.08]

Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity. [2011.06]

Effects of open-label lisdexamfetamine dimesylate on self-reported quality of life in adults with ADHD. [2011.05]

Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. [2011.03]

Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men. [2011]

Prediction of placebo response in 2 clinical trials of lisdexamfetamine dimesylate for the treatment of ADHD. [2011]

Effect of lisdexamfetamine dimesylate on sleep in children with ADHD. [2011]

Efficacy and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the day. [2010.12.14]

Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. [2010.06.24]

Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study. [2010.02]

Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. [2010]

Effects of lisdexamfetamine dimesylate treatment for ADHD on growth. [2010]

Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder. [2009.12]

A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. [2009.06.09]

Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. [2009.06]

Effect of lisdexamfetamine dimesylate on parent-rated measures in children aged 6 to 12 years with attention-deficit/hyperactivity disorder: a secondary analysis. [2008.09]

Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. [2008.09]

Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study. [2008.03]

Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. [2007.11.01]

Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. [2007.03]

Well-designed clinical trials possibly related to Vyvanse (Lisdexamfetamine)

Impact of stimulant pharmacotherapy on sleep quality: post hoc analyses of 2 large, double-blind, randomized, placebo-controlled trials. [2011.07]

Duration of effect of oral long-acting stimulant medications for ADHD throughout the day. [2010.08]

Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder. [2008.09]

Other research related to Vyvanse (Lisdexamfetamine)

Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder. [2012]

Double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in college students with ADHD. [2012]

Pharmacokinetics of Lisdexamfetamine Dimesylate After Targeted Gastrointestinal Release or Oral Administration in Healthy Adults. [2011.10.28]

Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. [2011.04]

Lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder in adults with a history of depression or history of substance use disorder. [2011.02]

Physician perception of clinical improvement in children with attention-deficit/hyperactivity disorder: a post hoc comparison of lisdexamfetamine dimesylate and mixed amphetamine salts extended release in a crossover analog classroom study. [2011]

Executive function deficits in children with attention-deficit/hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study. [2010.12]

Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD. [2010.12]

Focus on Lisdexamfetamine: A Review of its use in Child and Adolescent Psychiatry. [2010.11]

Understanding the Effect Size of Lisdexamfetamine Dimesylate for Treating ADHD in Children and Adults. [2010.09.13]

Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults. [2010.09]

Does prior exposure to stimulants in children with ADHD impact cardiovascular parameters from lisdexamfetamine dimesylate? [2010.09]

Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers. [2010.09]

Eosinophilic hepatitis in an adolescent during lisdexamfetamine dimesylate treatment for ADHD. [2010.06]

Lisdexamfetamine dimesylate: a prodrug stimulant for the treatment of ADHD in children and adults. [2010.05]

Assessing effects of treatment with lisdexamfetamine dimesylate for pediatric ADHD using a parental survey. [2010.04]

Effects of lisdexamfetamine dimesylate treatment for ADHD on growth. [2010.01]

Improvements in executive function correlate with enhanced performance and functioning and health-related quality of life: evidence from 2 large, double-blind, randomized, placebo-controlled trials in ADHD. [2010]

Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study. [2010]

Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study. [2009.12]

Lisdexamfetamine: a prodrug for the treatment of attention-deficit/hyperactivity disorder. [2009.11.15]

Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder. [2009.10]

Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. [2009.09]

Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder. [2009.08.03]

Lisdexamfetamine for treatment of attention-deficit/hyperactivity disorder. [2009.04]

The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults. [2009.01]

Lisdexamfetamine dimesylate: in attention-deficit hyperactivity disorder in adults. [2009]

Lisdexamfetamine: a prodrug stimulant for ADHD. [2008.08]

Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. [2008.07.17]

Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. [2008.07]

Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder. [2008.06]

Lisdexamfetamine dimesylate for childhood ADHD. [2008.05]

Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. [2008.01]

Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers. [2008]

Toxicity profile of lisdexamfetamine dimesylate in three independent rat toxicology studies. [2007.10]

Lisdexamfetamine Dimesylate and Mixed Amphetamine Salts Extended-Release in Children with ADHD: A Double-Blind, Placebo-Controlled, Crossover Analog Classroom Study. [2007.07.11]

Lisdexamfetamine. [2007]

Other possibly related research studies

Evolution of the treatment of attention-deficit/hyperactivity disorder in children: A review. [2008.05]

Pharmacologic treatment of ADHD: road conditions in driving patients to successful outcomes. [2008.01.08]

The effect of stimulant treatment for ADHD on later substance abuse and the potential for medication misuse, abuse, and diversion. [2007.11]

Gateways to clinical trials. [2008.01]

An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder. [2009.06]

Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy. [2010]

Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists. [2010.12]

Pharmacokinetic variability of long-acting stimulants in the treatment of children and adults with attention-deficit hyperactivity disorder. [2010.12.01]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014